parecoxib has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Gong, M; Wang, HM; Xu, LH; Yan, M; Zhang, XM | 1 |
| Chen, C; Peng, M; Wang, CY; Wang, FF; Wang, YL | 1 |
2 other study(ies) available for parecoxib and Cognition Disorders
| Article | Year |
|---|---|
Parecoxib mitigates spatial memory impairment induced by sevoflurane anesthesia in aged rats.
Topics: Aging; Anesthetics, Intravenous; Animals; Blotting, Western; Cognition Disorders; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Hippocampus; Isoxazoles; Male; Maze Learning; Memory; Memory Disorders; Methyl Ethers; Microscopy, Electron, Transmission; Rats; Rats, Sprague-Dawley; Sevoflurane; Synapses | 2012 |
The cyclooxygenase-2 inhibitor parecoxib inhibits surgery-induced proinflammatory cytokine expression in the hippocampus in aged rats.
Topics: Aging; Animals; Cognition Disorders; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Encephalitis; Gene Expression; Hippocampus; Interleukin-1beta; Isoxazoles; Male; Postoperative Complications; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2012 |